Genmab — November 2020

[Solsen]

Vi mangler SBs linier. Havde vi en linie heromkring ?

[Sukkeralf]

SB?

[Solsen]

Stockbull

[Solsen]

Target 2580 https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/87738_genmab_2237.JPG

[Solsen]

https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/87741_target_2580_gmab.JPG Det var til nytår at target var 2580. Men vi er over den linie nu i november. Prøv at aflæse næste niveau

[Plimsoller]

Target fo
r 2020 er 2700 Solsen

[E_L]

that is not a bad guess really, there is a nice AB=CD at 2722 and a 1.618 extension at
2720

[Plimsoller]

And equally good for the wallet

[E_L]

larger trendline resistance really only above 2900

[Solsen]

I think if Tapezza, Kesimpta, Darzalex still performing excellent. Amivantamab and TF is on its way to approval we reach a milestone with 3.000 DKK in 2021.

[Sukkeralf]

I agree.................and if a BsAb like PD-L1/4-1BB with the magnitude of 10 billion dollars or higher starts to show off then its hard to guess were we are going

[Sukkeralf]

early days still but valuation comes also early these days

[StockBull]

https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/88181_genmab_rykker.JPG Tror vi skal op og ligge og swinge mellem 2350 til 2650 kommende måneder. Har indikeret en mindre stejl kurve. Har selvfølgelig ikke ikke noget imod Genmab forbliver i den stejle kurve

[Helge_LarsenPI-redaktør]

Genmab/CEO: Darzalex suppleres af flere nye trækheste i 2021
https://www.proinvestor.com/investornyt/669340/genmab-ceo-darzalex-suppleres-af-flere-nye-traekheste-i-2021

[Solsen]

Du var sekundet hurtigere Helge. Bid mærke i, at JW forventer pæne indtægter fra Amivantamab i 2021.

[E_L]

did he not also compare Epcoritamab
to Dara in an interview or am i wrong now?

[Solsen]

Yes we forgot Epco Judith did tell that they will persude all b-cell indications.

[Solsen]

As I recall

[E_L]

and dont forget Dara , many abstracts at ASH and

[E_L]

Janssen Seeks Expanded Use of DARZALEX▼ (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Light Chain (AL) Amyloidosis https://www.businesswire.com/news/home/20201105005525/en/Janssen-Seeks-Expanded-Use-of-DARZALEX▼-daratumumab-Subcutaneous-Formulation-for-the-Treatment-of-Patients-with-Light-Chain-AL-Amyloidosis